Journal of Clinical Oncology
Articles in this Issue
A randomized phase 2 trial of lenvatinib plus pembrolizumab with or without stereotactic body radiotherapy in patients with metastatic renal cell carcinoma, low tumor burden, and stable disease (LASER).
TPS583 Background: Lenvatinib plus pembrolizumab (Len+P) is an established first-line regimen for metastatic clear cell re...
Durable outcomes in aggressive-variant prostate cancer treated with first-line carboplatin–docetaxel: A 10-year tertiary centre experience.
93 Background: Aggressive-variant prostate cancer (AVPC) is a rare but clinically significant subset of prostate cancer, o...
Sequential flotufolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy.
25 Background: Flotufolastat-F18 is a novel radio hybrid PSMA PET imaging agent that is FDA approved for imaging in men wi...
Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancer.
159 Background: Doublet therapy consisting of androgen deprivation therapy (ADT) plus an androgen receptor signaling inhib...
Multiomics approach for patient stratification and novel target identification in metastatic clear cell renal carcinoma (MeetUro 31): Preliminary analysis of radiomics features—A Meet-URO and AIRC study (NCT05782400).
425 Background: Artificial Intelligence can integrate clinic-pathological features, radiomics, genomic and transcriptomic...
Clinical significance of baseline serum IgG in metastatic renal cell carcinoma patients undergoing cytoreductive nephrectomy.
564 Background: This study aimed to explore the association between preoperative serum immunoglobulin G (IgG) levels and i...
Clinical and genomic predictors of sipuleucel-T (sip-T) outcomes in men with metastatic castration-resistant prostate cancer (mCRPC).
228 Background: Survival outcomes with sip-T in mCRPC are variable, and mechanisms driving these differences remain unknow...
TulmiSTAR-01: A phase I/II dose optimization study of tulmimetostat in combination with luxdegalutamide versus standard of care (SOC) in patients (pts) with progressive metastatic castrate-resistant prostate cancer (mCRPC).
TPS301 Background: Prostate cancer is the second leading cause of cancer death in men, and mCRPC remains difficult to trea...
A real-world US community-based evaluation of recurrence among non-muscle-invasive bladder cancer patients treated with bacillus Calmette-Guérin.
669 Background: Patients with high-risk (HR) non-muscle-invasive bladder cancer (NMIBC) are often treated with Bacillus Ca...
Homologous recombination repair (HRR) mutation in de novo metastatic hormone sensitive prostate cancer (mHSPC).
243 Background: Genomic alterations are becoming increasingly important to understand progression of disease and determine...
Treatment (Rx) patterns and survival outcomes in patients with metastatic chromophobe renal cell carcinoma (mchRCC).
465 Background: Chromophobe RCC represents a rare subtype of kidney cancer, which very infrequently metastasizes. Once met...
Performance of circulating tumor DNA as a biomarker in testicular seminoma and non-seminomatous germ cell tumor patients undergoing primary retroperitoneal lymph node dissection.
589 Background: Serum tumor markers have been the cornerstone in the detection and surveillance of testicular germ cell tu...
Genome-wide association to identify SNPs associated with severe adverse events and clinical outcomes in advanced renal cell carcinoma treated with nivolumab.
520 Background: Immune checkpoint inhibitors (ICIs) have markedly changed the management of advanced renal cell carcinoma...
Optimizing neoadjuvant ADT duration prior to radiotherapy in high-risk prostate cancer: Rationale and clinical need.
259 Background: Long-term androgen deprivation therapy (ADT) combined with radiotherapy (RT) is a standard treatment for h...
Profiling BCRAness phenotype in public prostate cancer datasets without homologous repair gene mutations.
223 Background: Co-inhibition of PARP and androgen receptor activity may enhance antitumor efficacy irrespective of HRR al...
Genomic profiling in circulating tumor DNA from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer: The KYUCOG-1901 study.
211 Background: Circulating tumor DNA (ctDNA) testing has emerged as a novel approach in cancer precision medicine. We inv...
Fruquintinib plus serplulimab as first-line therapy in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC): Updated efficacy and safety data from a multicenter, single-arm, phase II trial.
422 Background: Despite recent advancements, non-clear cell renal cell carcinoma (nccRCC) remains a significant therapeuti...
Circulating tumor DNA performance in primary retroperitoneal lymph node dissection: A stage-based analysis.
590 Background: Novel biomarkers appear to have use in the surveillance and treatment monitoring of testicular germ cell t...
A multicenter, open-label, phase II study of adaptive combination immunotherapy with VEGFR-TKI for advanced renal cell carcinoma.
TPS575 Background: The KEYNOTE-426 trial found superior progression-free survival (PFS) and overall survival (OS) with pem...
Impact of age, number of cycles of chemotherapy and presence of visceral metastases on PSA response in patients on triplet therapy (ADT + darolutamide + docetaxel) for mHSPC: UK real world data from the RECOMMEND study.
67 Background: Darolutamide has authorisation for treatment of metastatic hormone sensitive prostate cancer (mHSPC) in com...
Rescuing cancer immunotherapy with plasma exchange in bladder cancer 1 (ReCIPE-B1).
TPS898 Background: Enfortumab vedotin with pembrolizumab (EV/Pembro) is now first-line therapy for locally advanced or met...
Characterization of patients (pts) responding to enfortumab vedotin plus pembrolizumab (EV+P): Exploratory analysis from the phase 3 EV-302 trial of EV+P vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
746 Background: EV-302/KEYNOTE-A39 (NCT04223856) showed sustained efficacy benefits after long-term follow-up for pts with...
Racial disparities and trends in the in-hospital mortality for malignant prostate cancer.
39 Background: Prostate cancer is a leading cause of cancer-related death among men in the United States (U.S). Despite th...
IDeate-Prostate02: A phase 1/2, open-label umbrella substudy of ifinatamab deruxtecan-based treatment combinations or as monotherapy in participants with previously treated metastatic castration-resistant prostate cancer.
TPS297 Background: There is a high unmet need for effective therapies to improve outcomes from metastatic castration-resis...
External validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker in the randomised phase III CHHiP trial.
308 Background: Risk stratification in localised prostate cancer (PCa) based on clinicopathological parameters is inadequa...